Application of fluorocarbon nanoparticles of 131I-fulvestrant as a targeted radiation drug for endocrine therapy on human breast cancer.

BACKGROUND: Breast cancer is the most prevalent malignant tumor among women, with hormone receptor-positive cases constituting 70%. Fulvestrant, an antagonist for these receptors, is utilized for advanced metastatic hormone receptor-positive breast cancer. Yet, its inhibitory effect on tumor cells is not strong, and it lacks direct cytotoxicity. Consequently, there's a significant challenge in preventing recurrence and metastasis once cancer cells develop resistance to fulvestrant. METHOD: To address these challenges, we engineered tumor-targeting nanoparticles termed 131I-fulvestrant-ALA-PFP-FA-NPs. This involved labeling fulvestrant with 131I to create 131I-fulvestrant. Subsequently, we incorporated the 131I-fulvestrant and 5-aminolevulinic acid (ALA) into fluorocarbon nanoparticles with folate as the targeting agent. This design facilitates a tri-modal therapeutic approach-endocrine therapy, radiotherapy, and PDT for estrogen receptor-positive breast cancer. RESULTS: Our in vivo and in vitro tests showed that the drug-laden nanoparticles effectively zeroed in on tumors. This targeting efficiency was corroborated using SPECT-CT imaging, confocal microscopy, and small animal fluorescence imaging. The 131I-fulvestrant-ALA-PFP-FA-NPs maintained stability and showcased potent antitumor capabilities due to the synergism of endocrine therapy, radiotherapy, and CR-PDT. Throughout the treatment duration, we detected no notable irregularities in hematological, biochemical, or histological evaluations. CONCLUSION: We've pioneered a nanoparticle system loaded with radioactive isotope 131I, endocrine therapeutic agents, and a photosensitizer precursor. This system offers a combined modality of radiotherapy, endocrine treatment, and PDT for breast cancer.

A single-blinded pilot study assessing neurovascular contact by using high-resolution MR imaging in patients with trigeminal neuralgia.

OBJECTIVE: To assess the feasibility and utility of high-resolution three-dimensional magnetic resonance angiography (3D MRA) and contrast-enhanced 3D spoiled gradient-recalled imaging (3D SPGRI) for the purpose of visualization of neurovascular contact in trigeminal neuralgia (TN) patients. METHODS: Forty-five patients (25 males, 20 females; age range, 23-82 years; and mean age, 55.67+/-18.23 years) with unilateral typical TN and 36 control subjects (21 males, 15 females; age range, 25-85 years; mean age, 57.53+/-19.25 years) underwent high-resolution 3D MRA and contrast-enhanced 3D SPGRI assessment. The images were reviewed by two experienced neuroradiologists who were blinded to the clinical details. The imaging results were compared with the operative findings in all the patients; additionally, the degree of neurovascular contact was compared between the two groups based on MR imaging. RESULTS: In 45 patients with unilateral typical TN, the use of 3D MRA in conjunction with the contrast-enhanced 3D SPGRI identified neurovascular contact in 40 of the 42 symptomatic nerves; the contact was verified surgically. Based on the surgical findings, the sensitivity and specificity of MR imaging were 95.20% and 100%, respectively. Based on MRI, the compressing vessel (artery, vein) was correctly identified in 32 of the 39 cases verified by microvascular decompression. There was good agreement (K=0.77; 95% confidence interval, 0.54-0.99) between the position (medial, lateral, superior, and inferior) of the compressing vessel relative to the trigeminal nerve as defined by MR imaging and the surgical findings. The rates of vascular contact with the trigeminal nerve as observed on MRI were 31.94%, 48.89%, and 88.9% in the control subjects, asymptomatic, and symptomatic side of patients, respectively. CONCLUSION: The combined use of high-resolution 3D MRA and contrast-enhanced 3D SPGRI is an extremely sensitive and specific technique for demonstrating vascular contact with the trigeminal nerve in TN patients.